Search | Clinical Trials Finder

Conditions: Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Interventions: BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota

Conditions: Genital Warts
Interventions: GS-9191 ointment, GS-9191, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 25
States / cities: Tucson, Arizona • Beverly Hills, California • Mission Viejo, California + 20 more

Conditions: Atopic Dermatitis
Interventions: KP-413 Ointment; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Clinton Twp., Michigan • Portland, Oregon • Austin, Texas + 3 more

Conditions: Atopic Dermatitis
Interventions: OPA-15406, Vehicle ointment; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 10 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 20
States / cities: Los Angeles, California • San Diego, California • Denver, Colorado + 17 more

Conditions: Atopic Dermatitis
Interventions: YR001 ointment, Placebo; Drug · Other
Lead sponsor: Hangzhou Yirui Pharmaceutical Technology Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Boynton Beach, Florida • Hollywood, Florida • Weston, Florida + 1 more

Conditions: Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions: Artesunate ointment, Placebo ointment; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more

Conditions: Psoriasis
Interventions: CP-690,550 Ointment 1, Vehicle 1, CP-690,550 Ointment 2, Vehicle 2; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 8
States / cities: Mobile, Alabama • Los Angeles, California • Orange Park, Florida + 4 more

Conditions: Vulvar Vestibulitis
Interventions: 5% topical lidocaine ointment, Placebo cream; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: AIDS-related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Interventions: halofuginone hydrobromide, placebo, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Atopic Dermatitis
Interventions: Altabax (R), Vehicle and Locoid lipocream (R); Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 9 Months to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: New York, New York

Conditions: Plaque Psoriasis
Interventions: Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%), Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis Vulgaris
Interventions: CT327 0.05%, CT327 0.1%, CT327 0.5%, Placebo; Drug
Lead sponsor: Creabilis SA; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Hotsprings, Arkansas • San Ramon, California • Bay City, Michigan + 5 more

Conditions: Aging, Epigenetics, Inflammatory Mediators
Interventions: Rapamycin Topical Ointment, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 65 Years to 95 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Atopic Dermatitis
Interventions: TER-101, Vehicle; Drug
Lead sponsor: Teres Bio, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 12
States / cities: Scottsdale, Arizona • Encinitas, California • North Miami Beach, Florida + 9 more

Conditions: Non-melanomatous Skin Cancer
Interventions: Polyphenon E and Placebo; Drug
Lead sponsor: Frank Meyskens; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Orange, California

Conditions: Crohn's Disease
Interventions: 10% Metronidazole Ointment; Drug
Lead sponsor: S.L.A. Pharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Atopic Dermatitis
Interventions: TDM-180935 topical ointment 1.0%, TDM-180935 topical ointment 2.0%, TDM-180935 topical vehicle ointment 1, TDM-180935 topical vehicle ointment 2; Drug
Lead sponsor: Technoderma Medicines Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Rolling Meadows, Illinois • Covington, Louisiana • New Brighton, Minnesota + 4 more

Conditions: HIV Infections, Staphylococcal Infections
Interventions: Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%, Placebo; Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 4
States / cities: San Diego, California • Bethesda, Maryland • San Antonio, Texas + 1 more

Conditions: Alopecia Areata
Interventions: Crisaborole Topical Ointment, Placebo Topical Ointment; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Within-Subject Active vs. Placebo Topical Applications; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Atopic Dermatitis
Interventions: ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more

Conditions: Atopic Dermatitis
Interventions: 0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Melville, New York

Conditions: Skin Infections, Bacterial
Interventions: Retapamulin Ointment, 1%, Placebo ointment; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Months and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 32
States / cities: Tucson, Arizona • Anaheim, California • Fresno, California + 27 more

Conditions: Herpes Labialis
Interventions: Pritelivir 5% w/w ointment, Pritelivir ointment matching placebo, Zovirax® cream; Drug
Lead sponsor: AiCuris Anti-infective Cures AG; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Scottsdale, Arizona • Santa Rosa, California • Pinellas Park, Florida + 7 more

Search by objective public record fields.

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

CP-690-550 Ointment For Chronic Plaque Psoriasis

5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

Green Tea Extract in Treating Patients With Actinic Keratosis

Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease

Study of TDM-180935 in Atopic Dermatitis Patients

Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons

Topical Crisaborole in Patients with Alopecia Areata

Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes